Who is on it, and how far along Every drug ChEMBL records acting on POLA1, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Approved4 Gemcitabine Gemcitabine SponsorEli Lilly ModalitySmall molecule ActionInhibitor Open trials1,014 Fludarabine phosphate Fludarabine phosphate SponsorSanofi ModalitySmall molecule ActionInhibitor Open trials915 Cytarabine Cytarabine SponsorTeva Pharmaceutical Industries ModalitySmall molecule ActionInhibitor Open trials419 Clofarabine Clofarabine SponsorSanofi ModalitySmall molecule ActionInhibitor Open trials19 Phase 22 Troxacitabine Troxacitabine SponsorTakeda Pharmaceuticals USA ModalitySmall molecule ActionInhibitor Open trials1 Aspacytarabine Aspacytarabine SponsorBioSight Ltd. ModalitySmall molecule ActionInhibitor Open trials0
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: DNA polymerase (alpha/delta/epsilon) inhibitor. The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 33 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted Prospective Evaluation of Response to Treatment in Younger Adult Patients (18-60 Years) With Acute Myeloid Leukemia (AML) Cytarabine Phase 3 Not yet recruiting University Hospital, Toulouse Nov 19, 2026 A Phase 2 Study of Dynamic BH3 Profiling (DBP) Guided Combination Therapy in Subjects With R/R AML Cytarabine Phase 2 Not yet recruiting Dana-Farber Cancer Institute Nov 19, 2026 A Post-Marketing Trial to Evaluate the Safety and Efficacy of Quizartinib in Chinese Participants With Newly Diagnosed FMS-like Tyrosine Kinase 3-internal Tandem Duplication [FLT3-ITD] (+) Acute Myeloid Leukemia (AML) Cytarabine Phase 4 Not yet recruiting Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company Nov 19, 2026 First in Human Study of a Dual Targeting CD20 and CD19 CAR T Cell Treatment for Patients With B Cell Blood Cancers That Have Returned or Not Responded to Treatment Fludarabine phosphate Phase 1 Recruiting Cellogen Therapeutics Pvt. Ltd. Nov 19, 2026 Determining the Safety of CAR T-Cell Therapy for Lymphoma Fludarabine phosphate Phase 1 Not yet recruiting University of Chicago Nov 19, 2026 A Phase I/II Single-Arm, Open-Label, Exploratory Study Evaluating the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) Combined With Gemcitabine and Iparomlimab-Toripalimab in Borderline Resectable Pancreatic Cancer Gemcitabine Phase 1 / Phase 2 Not yet recruiting Tianjin Medical University Cancer Institute and Hospital Nov 18, 2026 T-Cell Therapy Using CD7 Negative T-Cells Expressing CD7 CAR Expressed In Pediatric Patients With Hematological Malignancies. Fludarabine phosphate Phase 1 Not yet recruiting St. Jude Children's Research Hospital Nov 17, 2026 Iparomlimab and Tuvonralimab Injection (QL1706)Combined With Chemotherapy (AG) and SBRT as First-Line Treatment for Locally Advanced Pancreatic Cancer Gemcitabine Phase 2 Active, not recruiting Tongji Hospital Nov 16, 2026 Effects of Hypoxia or Caffeine on 4km Time-trial Morning Cycling. Cytarabine Phase 4 Recruiting Liverpool John Moores University Nov 13, 2026 Disulfiram for Preventing Treatment Complications in Patients Undergoing CAR T-cell Therapy for Relapsed or Refractory Diffuse Large B-cell Lymphoma Fludarabine phosphate Phase 1 / Phase 2 Not yet recruiting University of Michigan Rogel Cancer Center Nov 12, 2026 BCMA/GPRC5D Dual-Target CAR-T Cell Immunotherapy for Relapsed/Refractory Multiple Myeloma Fludarabine phosphate Phase 1 Not yet recruiting Liping Dou Nov 10, 2026 A Multicenter, Prospective Single-arm Study of Multimodal Thermal Therapy Combined With Toripalimab and AG Chemotherapy in the Treatment of Advanced Pancreatic Cancer Gemcitabine Not applicable Not yet recruiting Ruijin Hospital Nov 10, 2026 An Exploratory Study of the Efficacy and Safety of SBRT Following Induction Therapy With Neoadjuvant Immunotherapy Combined With Chemotherapy in Muscle-Invasive Bladder Cancer Gemcitabine Not applicable Not yet recruiting Tianjin Medical University Cancer Institute and Hospital Nov 10, 2026 Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney Cancer Fludarabine phosphate Phase 2 Not yet recruiting Beth Israel Deaconess Medical Center Nov 9, 2026 A Study of SYS6010 Combined With Enlonstobart in Patients With Previously Systemic Treatment-Naive R/M Nasopharyngeal Carcinoma Gemcitabine Phase 3 Recruiting CSPC Megalith Biopharmaceutical Co.,Ltd. Nov 9, 2026 Thiotepa + TBI + Fludarabine + Etoposide for Allo-HSCT in Patients With R/R or High-risk Acute Leukemia Fludarabine phosphate Phase 2 Enrolling by invitation Guangdong Second Provincial General Hospital Nov 6, 2026 Asciminib-Based Induction Therapy for the Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Cytarabine Phase 1 Not yet recruiting City of Hope Medical Center Nov 3, 2026 Sequential Chemotherapy Followed by Ultrahypofractionated Radiotherapy for Muscle-Invasive Bladder Cancer Gemcitabine Phase 3 Not yet recruiting Assiut University Nov 3, 2026 Risk-Enabled Therapy After Initiating EV/Pembro for Bladder Cancer Gemcitabine Phase 2 Recruiting Fox Chase Cancer Center Nov 2, 2026 MAC vs RIC for Transplantation in FLT3-ITD-Mutated AML Guided by UHS-NGS MRD ( FLT3 - MAC vs RIC ) Cytarabine Not applicable Not yet recruiting First Affiliated Hospital of Zhejiang University Oct 29, 2026 To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma Fludarabine phosphate Phase 3 Not yet recruiting Kite, A Gilead Company Oct 29, 2026 Becotatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metastatic Nasopharyngeal Carcinoma Gemcitabine Phase 2 Not yet recruiting Sun Yat-sen University Oct 29, 2026 Low Dose Induction for Pediatric Acute Myeloid Leukemia Patients Cytarabine Not applicable Recruiting Azza Shibl Sayed Oct 9, 2026 Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Cytarabine Phase 2 Not yet recruiting National Cancer Institute (NCI) Oct 7, 2026 Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete Remission Clofarabine Not applicable Not yet recruiting Institute of Hematology & Blood Diseases Hospital, China Jun 12, 2026 Cord Blood Transplantation in Children and Young Adults With Blood Cancer Clofarabine Phase 2 Recruiting Memorial Sloan Kettering Cancer Center May 5, 2026 Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy Troxacitabine Phase 2 Recruiting CHA University Mar 25, 2026 Vyxeos® With Clofarabine for Pediatric AML Clofarabine Phase 1 Recruiting Princess Maxima Center for Pediatric Oncology Sep 5, 2025 Clofarabine Therapy in Locally Advanced or Metastatic Urothelial Carcinoma Clofarabine Phase 1 / Phase 2 Recruiting Ekaterina Laukhtina Jun 24, 2025 Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children Clofarabine Phase 2 Recruiting West China Second University Hospital Jun 15, 2025 Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease Clofarabine Phase 1 / Phase 2 Not yet recruiting Stanford University May 23, 2025 Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation Clofarabine Phase 2 Recruiting Nantes University Hospital Feb 12, 2024 Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT Clofarabine Phase 2 Recruiting Nantes University Hospital Jun 23, 2023
Show all 33Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2363042 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-21. ChEMBL and Open Targets